StockData
Arvinas, Inc. logo

Arvinas, Inc. (ARVN) stock

ARVNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 8/30
$6.46−0.28 (-4.15%)

Close on Nov 20, 2026Market cap $422.40MP/E 40.4Yield –

Arvinas free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Arvinas's free cash flow for the twelve months ending Jun 30, 2026 was -$208.80M. For fiscal 2025 it was -$275.70M. The highest annual figure on record is $554.70M in fiscal 2021.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$275.70M–
FY2024Dec 31, 2024-$261.10M–
FY2023Dec 31, 2023-$350.70M–
FY2022Dec 31, 2022-$280.30M-150.5%
FY2021Dec 31, 2021$554.70M–
FY2020Dec 31, 2020-$96.10M–
FY2019Dec 31, 2019-$46.90M–
FY2018Dec 31, 2018-$18.95M-562.1%
FY2017Dec 31, 2017$4.10M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$48.50M–
Q1 FY2026Mar 31, 2026-$70.50M–
Q4 FY2025Dec 31, 2025-$30.60M–
Q3 FY2025Sep 30, 2025-$59.20M–
Q2 FY2025Jun 30, 2025-$96.60M-294.8%
Q1 FY2025Mar 31, 2025-$89.30M–
Q4 FY2024Dec 31, 2024-$84.40M–
Q3 FY2024Sep 30, 2024-$128.70M–
Q2 FY2024Jun 30, 2024$49.60M–
Q1 FY2024Mar 31, 2024-$97.60M–
Q4 FY2023Dec 31, 2023-$83.20M–
Q3 FY2023Sep 30, 2023-$85.90M–
Q2 FY2023Jun 30, 2023-$89.30M–
Q1 FY2023Mar 31, 2023-$92.30M–
Q4 FY2022Dec 31, 2022-$72.30M–
Q3 FY2022Sep 30, 2022-$68.80M-110.1%
Q2 FY2022Jun 30, 2022-$80.00M–
Q1 FY2022Mar 31, 2022-$59.20M–
Q4 FY2021Dec 31, 2021-$37.60M–
Q3 FY2021Sep 30, 2021$680.20M–
Q2 FY2021Jun 30, 2021-$47.90M–
Q1 FY2021Mar 31, 2021-$40.00M–
Q4 FY2020Dec 31, 2020-$30.77M–
Q3 FY2020Sep 30, 2020-$23.79M-3674.3%
Q2 FY2020Jun 30, 2020-$23.23M–
Q1 FY2020Mar 31, 2020-$18.31M–
Q4 FY2019Dec 31, 2019-$18.00M–
Q3 FY2019Sep 30, 2019$665.60K–
Q2 FY2019Jun 30, 2019-$16.46M–
Q1 FY2019Mar 31, 2019-$13.11M-170.3%
Q4 FY2018Dec 31, 2018-$12.88M-146.4%
Q3 FY2018Sep 30, 2018-$11.93M–
Q2 FY2018Jun 30, 2018-$12.81M–
Q1 FY2018Mar 31, 2018$18.66M–
Q4 FY2017Dec 31, 2017$27.72M–

More Arvinas figures

See a number that looks wrong?